Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1140678

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1140678

Global Enteral Feeding Formulas Market - 2022-2029

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

Enteral Feeding Formulas Market is expected to reach at a CAGR of 6.8% during the forecast period (2022-2029).

Enteral feeding is the delivery of a nutritionally complete feed containing fat, protein, minerals, carbohydrate, water, and vitamins, directly to the stomach, duodenum, or jejunum. There are various types of tubes available for enteral feed formulae, such as gastrostomy, nasojejunal tube, nasogastric tube, and jejunostomy. These tubes are made of silicone, polyurethane, or PVC and are of different lengths from 30 to 43 inches, with diameters from 8 to 14 inches for adults. Some of the other equipment used for enteral feeding include an administration reservoir (bottle, feed bag, etc.), syringes, and enteral pump. Various routes are used in the administration of the necessary nutrients are cost-effective, healthy, and also a choice for the invasive process. Enteral feeding is preferred for patients with malnutrition due to eating disorders such as anorexia nervosa, dysphagia, and stomach infections, among others.

Market Dynamics

The demand for enteral feeding formula demand is surging with rising therapeutic uses of enteral feeding formula coupled with the introduction of new technologically advanced enteral feeding formula. In addition, the growing geriatric population globally and the rising prevalence of preterm births are also boosting the market growth.

The high prevalence rate of chronic disorders is driving the market growth

Increasing incidences of chronic disorders, such as cardiovascular diseases, cancer, diabetes, and (Coronary Obstructive Pulmonary Disorders) COPD are expected to drive the growth of the enteral feeding formulas market.

As per the International Diabetes Federation, diabetes patients spent US$ 966 billion in health expenditure in 2021, of which, 9 percent of total spending on adults. Around 537 million adults (20-79 years) are living with diabetes currently, and by 2045 this is projected to rise to 783 million. The proportion of type 2 diabetes people is increasing in most countries. Around 541 million adults' people are at increased risk of developing type 2 diabetes. population was suffering from some form of cardiac disease; it is further estimated that this prevalence is likely to increase to 45% by 2035. According to the Centers for Disease Control and Prevention (CDC) of the U.S., about half of the population (47%) of the United States have at least one of these three risk factors.

For the treatment of these chronic diseases, a longer hospital stays and recovery time is required. Patients face problems in swallowing food, so, external nutrition is given to the patient through the tube. Hence, the increase in the cases of chronic diseases, such as cancer and cardiovascular diseases, is expected to drive the growth of the market over the forecast period.

Lack of reimbursement is hampering the growth of the enteral feeding formulas market

The lack of reimbursement of enteral feeding formula is expected to hamper the usage of enteral feeding formula and lower the adoption rate of the enteral feeding formula in the forecast period.

Market Segmentation:

The global enteral feeding formulas market is segmented based on product, flow type, stage, application, and end-users.

The oncology segment is expected to hold a major market share in the enteral feeding formulas market

The burden of cancer is growing rapidly worldwide. Cancer is expected to grow rapidly during the forecast period. The WHO has reported that cancer is the second leading cause of death globally and is responsible for 10 million deaths or one death in 6 deaths in 2020 and worldwide. Also, around 70% of deaths from cancer occur in low and middle-income countries. WHO stated that around 17.9 million people die every year with cardiovascular diseases, and globally, it accounts for 32% of deaths. The majority of tumor-bearing patients suffer from cancer cachexia, which causes insulin resistance, increased lipolysis with loss of body fat, increased protein turnover, and loss of muscle mass, causing loss of appetite and weight.

Also, there are several complications and side effects in the patients while cancer treatment, including difficulty in chewing and swallowing solid food, mucositis sores in the mouth, altered saliva level, which makes it difficult to swallow. To improve the clinical condition of patients, delivery of nutrition is very difficult for the cancer patients to take the food orally, hence, the nutrition is supplied by enteral feeding tubes to help them maintain the body mass.

The standard formulas segment is expected to hold the largest market share during the forecast period

By product, the market is classified into standard and disease-specific formulas. Among these, the standard formulas segment accounted for the largest market share due to its high demand for enteral nutrition and basic clinical nutrition, high commercial availability, and growing investment by major companies. The standard formulas segment is further segmented into polymeric formulas and monomeric formulas. There are different varieties of standard formulas available with the growing demand for low-cost nutrient formulations. The demand for standard tube feeds is high among volume-sensitive patients or patients with congestive heart failure, Syndrome of Inappropriate Diuretic Hormone (SIADH), and renal failure.

On the other hand, the disease-specific formulas are expected to grow at the fastest growth rate during the forecast period, 2020 to 2027 due to growing improvements in enteral feeding formula and devices with the rising prevalence of several chronic diseases. The disease-specific formulas segment is further segmented into renal, diabetic, hepatic, pulmonary, and others. Growing awareness among healthcare professionals and the patient population towards the benefits of enteral medical foods is one of the major factors driving the segment growth.

By Stage, the Adult Segment held the largest market share in 2019

Based on stage, the market is segmented into adults and pediatrics. The adult segment accounted for the largest market share in 2019, due to the growing adoption of tube feed among adults. The enteral feeding can be performed by the syringe method, gravity drip method, and pump method in adults. According to a study by the Medical Nutrition International Industry, the financial cost associated with malnutrition or undernutrition in the European Union is around US$ 185 billion. About one in six individuals are affected by malnutrition globally. The growing demand for such nutrition formulations in the adult population is one of the major factors boosting segment growth.

On the other hand, the pediatrics segment is expected to grow significantly over the forecast period, due to the rising number of premature births and increasing prevalence rate of malnutrition among hospitalized children. For instance, as per the report published by UNICEF-WHO-World Bank, more than one in five that is around 149.2 million children were stunted in 2020. Pediatric patients with a dysfunctional gastrointestinal tract cannot ingest nutrients orally and thus administer enteral feeding. Some pediatric patients suffering from gastrointestinal disorders, such as severe gastroesophageal reflux, allergies, food refusal behavior, and metabolic disorders are also provided tube feeding.

By End-user, Home care is expected to grow significantly over the forecast period.

Home care is expected to grow at the fastest growth rate over the forecast period, owing to the rising number of patients receiving home enteral feeding with growing awareness towards balanced nutrition. There is a rise in the adoption of enteral feeding formulas among home healthcare patients. A policy was developed in combination with the National Institute for Clinical Excellence (NICE) which has revolutionized the healthcare service for patients on nutrition supplements and has enhanced the service delivery. Geographical Presentation:

North America region holds the largest market share in the global enteral feeding formulas market

North America region is dominating the global enteral feeding formulas market accounted for the largest market share in 2021, due to several factors, such as the growing geriatric population, rising prevalence of preterm birth, and the increasing number of chronic disease patients. The United States is the major contributor to the growth of the enteral feeding formulas market. In the U.S., it is projected that the number of people aged above 65 years will more than double by 2060. The growing geriatric population would increase the cases of chronic diseases, such as cancer and diabetes, which will lead to an increase in the hospital stay of the patient. Also, according to the WHO, around 15 million babies are born preterm, and this number is rising. Hence, the market is expected to grow further in this region over the forecast period.

Asia-Pacific region is growing at the fastest CAGR during the forecast period.

The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period. The market in Japan, China, and India is likely to grow significantly during the forecast period, due to the large presence of patients suffering from chronic diseases and disorders, increasing incidences of preterm births, growing healthcare expenditure, rapidly developing healthcare infrastructure, and growing demand in these countries.

Competitive Landscape:

The enteral feeding formulas market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Fresenius Kabi AG, B. Braun Melsungen AG, Victus, Inc., Hormel Food Corp., Danone S.A., Nestle S.A., Mead Johnson Nutrition Company, Global Health Products, Inc., Meiji Holdings Co., Ltd., Trovita Health Science, among others.

B. Braun Melsungen AG

Overview:

B. Braun is majorly involved in the manufacturing, marketing, and distributing of various healthcare products and services in the fields of medical technology, medical services, and pharmaceutical products. The company's product range comprises around 5,000 products of which 95% of the products are manufactured by the company. Some of the major product lines manufactured by the company include disposables required for infusion, nutrition and pain therapy, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, and stoma and wound care products. B. Braun has a presence in 64 countries and develops products in 18 therapy fields of the healthcare industry. The company operates its business through five business divisions which include hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM), and other sales.

Product Portfolio:

Enteral Nutrition Pumps:

Enteroport® plus: Enteral nutrition pump

Accessories Enteroport® plus: Accessories for the enteral nutrition pump Enterport® plus

Feeding Tubes

Nutritub®: Polyurethane feeding tube

Gastric Tubes: Nasogastric and naso-intestinal PVC tubes for short-term use only.

Duodenal Tubes: PVC tube

Others

Key Development:

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Enteral Feeding Formulas market globally. For instance,

In June 2020, Hormel Foods has been named to the 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies. This increases the credibility of the company and establishes a good name in the market

On 29th April 2022, Fresenius Kabi launched its new Enteral nutrition product app. That app is available for healthcare professionals in the United Kingdom and the Republic of Ireland.

COVID-19 Impact Analysis

The demand for enteral feeding formulas is growing with the increasing number of COVID-19 cases in hospitals. In 2020, the critical care segment is rapidly growing in the enteral feeding formula industry due to the rising number of COVID-19 patients, which are also leading to the consumption of nutritional feeding formulas more towards the patients with ventilators.

Growing awareness among healthcare professionals regarding hospital-associated malnutrition is anticipated to boost the usage rate of enteral feeding formulas in hospitals. Moreover, the increasing number of ICU admissions during COVID-19, rising demand for enteral formulations among critically ill patients, are likely to boost the market growth.

Product Code: DMHCIT2725

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Stage
  • 3.3. Market Snippet by Flow Type
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by End-User
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising prevalence of chronic diseases and disorders
    • 4.2.2. Growing number of preterm births
    • 4.2.3. Technological advancement in feeding formulas
    • 4.2.4. XX
  • 4.3. Restraints
    • 4.3.1. Complications associated with enteral feeding
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Disease-specific Formulas*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.2.3. Pulmonary Formulas
    • 7.2.4. Diabetic Formulas
    • 7.2.5. Hepatic Formulas
    • 7.2.6. Renal Formulas
    • 7.2.7. Others
  • 7.3. Standard Formulas
    • 7.3.1. Monomeric Formulas
    • 7.3.2. Polymeric Formulas

8. By Stage

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
    • 8.1.2. Market Attractiveness Index, By Stage Segment
  • 8.2. Adults *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Pediatrics

9. By Flow Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
    • 9.1.2. Market Attractiveness Index, By Flow Type Segment
  • 9.2. Intermittent Feeding Flow*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. Continuous Feeding Flow

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 10.1.2. Market Attractiveness Index, By Application Segment
  • 10.2. Oncology*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3. Diabetes
  • 10.4. Neurology
  • 10.5. Gastroenterology
  • 10.6. Critical Care
  • 10.7. Others

11. By End-User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
    • 11.1.2. Market Attractiveness Index, By End-User Segment
  • 11.2. Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 11.3. Homecare Agencies & Hospices
  • 11.4. Long-term Care Facilities
  • 11.5. Nursing Homes
  • 11.6. Others

12. By Region

  • 12.1. Introduction
  • 12.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 12.3. Market Attractiveness Index, By Region
  • 12.4. North America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. U.S.
      • 12.4.8.2. Canada
      • 12.4.8.3. Mexico
  • 12.5. Europe
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. Germany
      • 12.5.8.2. U.K.
      • 12.5.8.3. France
      • 12.5.8.4. Italy
      • 12.5.8.5. Spain
      • 12.5.8.6. Rest of Europe
  • 12.6. South America
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 12.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.6.8.1. Brazil
      • 12.6.8.2. Argentina
      • 12.6.8.3. Rest of South America
  • 12.7. Asia Pacific
    • 12.7.1. Introduction
    • 12.7.2. Key Region-Specific Dynamics
    • 12.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
    • 12.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
    • 12.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 12.7.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.7.8.1. China
      • 12.7.8.2. India
      • 12.7.8.3. Japan
      • 12.7.8.4. Australia
      • 12.7.8.5. Rest of Asia Pacific
  • 12.8. Middle East and Africa
    • 12.8.1. Introduction
    • 12.8.2. Key Region-Specific Dynamics
    • 12.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 12.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
    • 12.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
    • 12.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Abbott Laboratories*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Fresenius Kabi AG
  • 14.3. B. Braun Melsungen AG
  • 14.4. Victus, Inc.
  • 14.5. Danone S.A.
  • 14.6. Nestle S.A.
  • 14.7. Mead Johnson Nutrition Company
  • 14.8. Health Products, Inc.
  • 14.9. Meiji Holdings Co., Ltd.,
  • 14.10. Trovita Health Science (List Not Exhaustive)

15. DataM Intelligence

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!